138 filings
Page 3 of 7
POS AM
1spu26kw5s3mm34xsu
1 May 23
Prospectus update (post-effective amendment)
5:19pm
S-8
an9xahw5mbn
1 May 23
Registration of securities for employees
5:15pm
6-K/A
a36d8zpcawwdyxa5nhm
1 May 23
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
4:03pm
6-K
y2piu5x2ne5 zddze6
14 Mar 23
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
10:46am
6-K
jbi9sb8g
2 Mar 23
Prenetics Announces Formation of Scientific Advisory Board to Support
7:39am
6-K
d85n1
19 Jan 23
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
8:49am
424B3
fgjwe
17 Jan 23
Prospectus supplement
6:12am
6-K
1h66w3aq8 wnswz2
10 Jan 23
Current report (foreign)
7:48am
6-K
dfwww9avos57ag3l
16 Dec 22
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
8:06am
EFFECT
zle3evp39k1q3
15 Dec 22
Notice of effectiveness
12:15am
POS AM
5pl 40si5k
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
6-K
4oa b6vu8y
30 Nov 22
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
6:15am
6-K
inhx6 re0vcs1pexx27w
10 Nov 22
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
4:04pm
S-8
dq6cca r2u
19 Oct 22
Registration of securities for employees
9:20pm
6-K
bnfm5ntygs6i9u6 ry
22 Sep 22
Current report (foreign)
6:06am
6-K
7025vex0 vndshps01
9 Sep 22
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
4:32pm
424B3
kvamkrosv
1 Jul 22
Prospectus supplement
4:10pm
EFFECT
b6ialg5 nr21w5xmr
1 Jul 22
Notice of effectiveness
12:15am
F-1/A
8iaa48ljyjmlyly82 7c
28 Jun 22
Registration statement (foreign) (amended)
4:02pm